LOAD MORE
You're viewed all 13 products
Rabeprazole
References
FAQ's
References
- Souda, Shigeru; Ueda, Norihiro; Miyazawa, Shuhei; Tagami, Katsuya; Nomoto, Seiichiro; Okita, Makoto; Shimomura, Naoyuki; Kaneko, Toshihiko; Fujimoto, Masatoshi, Pyridine derivatives, pharmaceutical compositions comprising the same, the use of the same for the manufacture of medicaments having therapeutic or preventative value, and a process for preparing the same, Eisai Co., Ltd., Japan, EP0268956A2, June 1, 1988
- El-Gindy, Alaa; El-Yazby, Fawzy; Maher, Moustafa M., Spectrophotometric and chromatographic determination of rabeprazole in presence of its degradation products, Journal of Pharmaceutical and Biomedical Analysis, Volume: 31, Issue: 2, Pages: 229-242, 2003
Frequently Asked Questions
What role do regulatory authorities play in the monitoring of Rabeprazole impurities?
Regulatory authorities play a crucial role in monitoring and setting standards for Rabeprazole impurities to ensure the safety and efficacy of the drug.
Are Rabeprazole impurities evaluated during clinical trials?
Yes, Rabeprazole impurities are evaluated during clinical trials to assess their safety and ensure compliance with regulatory standards.
Can Rabeprazole impurities affect the stability of the drug?
Yes, impurities in Rabeprazole can impact the drug's stability.
What are the temperature conditions required to store Rabeprazole impurities?
Rabeprazole impurities are stored at a regulated room temperature of 2-8°C or as specified on the Certificate of Analysis (CoA).
Note: Products protected by valid patents by a manufacturer are not offered for sale in countries having patent protection. The sale of such products constitutes a patent infringement, and its liability is at the buyer's risk.